Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled trial of OTO-104 for unilateral Meniere's disease
2018-001464-35Phase 3Unknown
- Sponsor
- Otonomy, Inc.
- Start
- Jul 2018
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Meniere Disease comparing OTO-104 arm with Placebo arm (2 arms). Primary endpoint: Number of definitive vertigo days at Week 12. Status: unknown.
02
Drugs
Otividex
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2018-001464-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001464-35.